Table 1. Product and referral characteristics of antibiotics that went through referral procedures, European Union, 2007–2020 (n = 15).
| Type of antibiotics | Article | Competent authoritya | Year of EC decision |
|---|---|---|---|
| Cephalosporins | |||
| Ceftazidime | 30 | EC | 2011 |
| Cefuroxime axetil | 30 | EC | 2012 |
| Cefuroxime sodium | 30 | EC | 2012 |
| Ceftriaxone | 30 | EC | 2014 |
| Penicillins | |||
| Amoxicillin/clavulanic acid | 30 | EC | 2009 |
| Piperacillin/tazobactam | 30 | EC | 2011 |
| Amoxicillin | 30 | EC | 2015 |
| Fluoroquinolones | |||
| Ciprofloxacin | 30 | FR | 2008 |
| Levofloxacin | 30 | EC | 2012 |
| Carbapenems | |||
| Meropenem | 30 | EC | 2009 |
| Imipenem/cilastatin | 30 | NL | 2011 |
| Glycopeptides | |||
| Teicoplanin | 30 | EC | 2013 |
| Vancomycin | 31 | ES | 2017 |
| Polymyxins | |||
| Colistin/colistimethate sodium | 31 | EC | 2014 |
| Other antibacterial medicines | |||
| Fosfomycin | 31 | DE | 2020 |
DE: Germany; EC: European Commission; ES: Spain; FR: France; NL: the Netherlands.
a Competent authority starting the procedure.